BioNTech Founders Launch New mRNA Venture as Patent Storms Gather and Stock Marks Time

BioNTech co-founders launch a new mRNA biotech firm by 2026 while facing multiple patent lawsuits and a €531.9M net loss. Stock hovers near €80 with neutral momentum.

BioNTech is navigating a rare moment of simultaneous upheaval and opportunity. Its co-founders Ugur Sahin and Özlem Türeci are spinning off a new biotech company focused on next-generation mRNA innovations, while a widening ring of patent lawsuits threatens to complicate the legacy vaccine business. The stock, meanwhile, remains stuck in a tight range — closing Friday at €80.20, up a marginal 0.25 percent on the day and virtually unchanged over the past month.

The new entity, which Sahin and Türeci aim to build by the end of 2026, will receive certain rights and mRNA technologies from BioNTech. In return, the Mainz-based company will take a minority stake. The move allows BioNTech to sharpen its focus on bringing its oncology pipeline to market — a strategy that has already yielded 15 Phase 3 studies scheduled to run by year-end, with the goal of becoming a multi-product cancer therapy company by the early 2030s.

But even as management clears space for the oncology pivot, legal risks are multiplying. Arbutus Biopharma and Genevant Sciences have filed three new patent lawsuits in Canada and Europe targeting the lipid nanoparticle technology used in BioNTech and Pfizer’s Comirnaty vaccine. The suits expand on existing U.S. litigation and demand damages and permanent injunctions across multiple jurisdictions. The campaign gained momentum after Arbutus secured a $178 million settlement from Moderna in a similar dispute. Sanofi has added its own patent complaint over the Covid shot, further crowding the legal battlefield.

The timing is awkward. BioNTech’s vaccine revenue has collapsed, leaving the company to finance a costly transformation. In the first quarter of 2026, revenue plunged to €118.1 million, and the net loss widened to €531.9 million. Full-year guidance issued by management points to sales between €2.0 billion and €2.3 billion, while research and development spending is forecast to run between €2.2 billion and €2.5 billion — primarily directed at the oncology program. That makes the patent threat more than a legal inconvenience: any sizable award or injunction could divert cash needed for the pipeline.

BioNTech does have a deep cushion. It held roughly €16.8 billion in cash and equivalents at the end of March, giving it ample runway to absorb legal costs and sustain R&D investment while the clinical work plays out.

The stock’s recent price action reflects the standoff between those resources and the multiple uncertainties. At €80.20, the shares trade 1.23 percent above their 50-day moving average of €79.23 — a thin technical floor — but remain 5.54 percent below the 200-day average of €84.90. The Relative Strength Index sits at 49.3, squarely in neutral territory and signaling a lack of directional conviction. The January 52-week high of €105.80 now lies 24.2 percent above the current level, and the stock has lost 16.28 percent over the past twelve months. The company’s market capitalisation stands at roughly €20 billion.

All eyes now turn to August 4, when BioNTech reports second-quarter earnings. Investors will look for signs that the oncology strategy is beginning to show in the top line — and for any update on how the patent battles are affecting cost guidance. Until then, the shares look likely to remain caught between a shrinking vaccine business, a promising but expensive new drug pipeline, and a legal docket that keeps getting longer.